Our platform technology allows us to engineer novel Hybrid Interferons targeted against specific diseases, each with a large unmet medical need and clear commercial market.

Our lead candidate - Alfacyte - is a broad-spectrum antiviral in development as a therapeutic for RSV.

Latest News

Manufacturing Chemist article: Hybrid interferons: developing a novel drug class

ILC Therapeutics’ COO Dawn Firmin spoke with Manufacturing Chemist on the challenges in developing a novel drug class, and the Company’s journey so far and how it addressed some of these key challenges.
Read More on Manufacturing Chemist article: Hybrid interferons: developing a novel drug class »

ILC Therapeutics completes £2.5m financing and bolsters C-suite

ILC Therapeutics, a specialist developer of hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications, announces that it has successfully completed a fundraise of £2.5m.

Read More on ILC Therapeutics completes £2.5m financing and bolsters C-suite »

ILC completes investment round and appoints Dr Owain Millington as Vice President and Head of Preclinical Development

Scottish biotech ILC Therapeutics has completed its most recent investment round and is on track to commercialise a suite of antiviral medicines for the treatment of respiratory infections including SARS-CoV-2.

Read More on ILC completes investment round and appoints Dr Owain Millington as Vice President and Head of Preclinical Development »